A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Silver Sulfadiazine (SILVADENE)

Sulfonamide Antibacterial class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval1973-11-26
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$15.4M in CY2024 Part D spend933K claims · 620K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.110/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.232
Across all dosage forms in distribution.
Highest NADAC
$0.317
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Silver Sulfadiazine used for?

Silver Sulfadiazine is a Sulfonamide Antibacterial medication tracked in Medicare Part D.

Is there a generic for Silver Sulfadiazine?

No. Silver Sulfadiazine is brand-only with no generic equivalents currently in market.

How much does my plan pay for Silver Sulfadiazine?

Across 329 Part D plans, Silver Sulfadiazine averages $0.232/unit (NADAC). Lowest available: $0.110/unit. Highest in distribution: $0.317/unit.

Is Silver Sulfadiazine on the FDA shortage list?

No. Silver Sulfadiazine is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Sulfonamide Antibacterial2 alternatives in D1
01
Sodium Sulfacetamide, Sulfur
Brand: SODIUM SULFACETAMIDE - SULFUR WASH
$0.230Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Sulfadiazine
Sulfonamide Antibacterial
$14.98Lowest NADAC
1Generic mfrs
$1.2MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.